BHSTConsumer Defensive · Packaged FoodsThe 4 Wall Street analysts covering BioHarvest Sciences, Inc. hold a median 12-month price target of $13 — +525.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores BioHarvest Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (83): Smaller than most of the companies we track.
Momentum (4): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BHST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +525.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Maxim Group | Maintains | Buy | $12 → $5.00 |
| 12 Aug 2026 | Roth Capital | Maintains | Buy | $10 → $8.00 |
| 19 Feb 2026 | Roth Capital | Initiates | Buy | — |
| 19 Feb 2026 | Roth Capital | Initiates | Buy | $10 |
| 8 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Dec 2024 | Maxim Group | Initiates | Buy | — |
| 11 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Dec 2024 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BHST appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 64% of US stocks
Cheaper than 42% of US stocks
Cheaper than 82% of US stocks
Higher than 36% of US stocks
Higher than 46% of US stocks
Higher than 73% of US stocks
Higher than 20% of US stocks
Higher than 13% of US stocks
Higher than 10% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioHarvest Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of BioHarvest Sciences Inc.'s Q2 2026 earnings conference call.
Why it matters — The earnings call transcript provides direct insight into management's discussion of the company's quarterly financial results and strategic outlook.
BioHarvest Sciences reported Q2 2026 revenue of $8.8 million, up 3.8% year-over-year, and announced its first manufacturing and supply agreement within its CDMO business.
Why it matters — The revenue growth and the first CDMO agreement signal early commercial traction beyond the company's core business.
BioHarvest Sciences reported second-quarter revenue of $8.8 million, a 3.8% increase year-over-year, and also secured a manufacturing deal for a premium fragrance compound.
Why it matters — The revenue growth and new manufacturing agreement signal expansion in both core operations and new product verticals for BioHarvest.
BioHarvest Sciences Inc. reported a second-quarter loss of $0.17 per share, wider than the Zacks Consensus Estimate of a $0.13 loss and larger than the $0.15 loss posted a year earlier. The company also lagged revenue estimates for the quarter.
Why it matters — BHST watchers would care because the company missed analyst expectations on both earnings and revenue, marking a deterioration from the prior-year period.
BioHarvest Sciences reported Q2 2026 revenue of $8.8 million, up 3.8% year-over-year, and announced its first CDMO manufacturing agreement for a two-year, 20-ton commercial production program of a rare botanical fragrance ingredient for a UAE-based customer.
Why it matters — The CDMO agreement signals a new revenue stream that management expects to drive profitable growth for the company's CDMO business.
The 4 Wall Street analysts covering BioHarvest Sciences, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering BioHarvest Sciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioHarvest Sciences, Inc. 41 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, BioHarvest Sciences, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +525.0% from the last close, and Ticker Nerd's factor model ranks BioHarvest Sciences, Inc. 41 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioHarvest Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $15 over the next 12 months.
BioHarvest Sciences, Inc. returned -77.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Bioharvest Sciences Inc. is a biotechnology company that focuses on developing innovative solutions for functional food and plant-based nutritional products.
The most recent item we track (Seeking Alpha, 11 Aug 2026): "BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of BioHarvest Sciences Inc.'s Q2 2026 earnings conference call.
Bioharvest Sciences Inc. is a biotechnology company that focuses on developing innovative solutions for functional food and plant-based nutritional products. The company’s primary function is to harness the benefits of natural compounds using a proprietary biofarming technology that allows for the production of plant-derived nutrients on an industrial scale. This technology is notable for producing bioactive compounds without the need for complex plant cultivation processes, making it a sustainable and scalable approach to nutraceutical production. Bioharvest Sciences Inc. impacts several industries, including health and wellness, alternative medicine, and environmental sustainability sectors. By offering products that are rich in essential nutrients and antioxidants, the company caters to the growing consumer demand for healthier lifestyles and plant-based alternatives. As part of its market significance, Bioharvest stands out for its potential to transform agricultural practices and improve access to high-quality nutritive compounds globally, thus contributing to the advancement of the food and nutrition industries.
CEO Dr. Zaki Rakib Ph.D. · 89 employees · Canada · https://www.bioharvest.com